Novel Synthesis, Characterization and Biological Evaluation of Substituted Pyrazolidine-3, 5-Dione

Total Page:16

File Type:pdf, Size:1020Kb

Novel Synthesis, Characterization and Biological Evaluation of Substituted Pyrazolidine-3, 5-Dione Central JSM Chemistry Research Article *Corresponding author Neeraj Upmanyu, School of Pharmacy & Research, By-Pass Road, Bhanpur, Bhopal (M.P.) -462027, Tel: 91- Novel Synthesis, 9425-128642; Email id: Submitted: 06 July 2015 Characterization and Biological Accepted: 31 August 2015 Published: 02 Spetmeber 2015 ISSN: 2333-6633 Evaluation of Substituted Copyright © 2015 Upmanyu et al. Pyrazolidine-3, 5-Dione OPEN ACCESS 1 1,2 1 Rohit Singh , Neeraj Upmanyu *, Manish Gupta and Pallavi Keywords Prasad3 • Pyrazolidine-3, 5-dione 1Department of Pharmaceutical Chemistry, R.K.D.F. College of Pharmacy, India • Benzoic acid 2School of Pharmacy and Research, Peoples University, India • Antibacterial & Anti-inflammatory 3School of Pharmaceutical Sciences, India Abstract An efficient lead molecule Pyrazolidine-3, 5-dione derivative has been developed as anti-inflammatory and antibacterial agents. In the present investigation, the compounds (RS-1 to RS-10) were synthesized according to Scheme 1 using 4-substituted benzoic acid as starting material. This acid is converted into the respective ester (R1 to R5) and then ester is converted into hydrazide (R2A1 to R2A5 & R2B1 to R2B5), and finally into the pyrazolidine-3,5-diones (tested compound). The compounds were evaluated for their anti-inflammatory activity by the carrageen an-induced paw edema method and anti-bacterial activity using zone of inhibition method. Out of these compounds RS-6, RS-9, RS-10, and RS-2 were found to be the most active synthesized compounds, with significant anti-inflammatory activity. The Structure Activity Relationship (SAR) of these synthesized compounds showed that substitution with Nitro and Chloro group at para position of phenyl ring is produce optimum activity, as among all the synthesized compounds, the most active ones were RS-6, RS-9, and RS-10. Another structural feature of all the synthesized compounds was that phenyl substitution over Nitrogen of Pyarazolidine-3,5-dione also produce appreciable activity. Therefore these synthesized molecules can be considered as lead molecules for future investigations. ABBREVIATIONS on heterocycles and the chemistry of Pyrazolidine-3,5-dione has received considerable attention owing to their synthetic and FAB: Fast Atom Bombardment; TLC: Thin Layer effective biological importance. Pyrazolidine-3,5-dione moiety Chromatography; IR: Infra Red; OECD: Organization for Economic has been incorporated into a wide variety of therapeutically Cooperation and Development INTRODUCTION antimicrobial [1]. There are many marketed drugs containing the interesting drug candidates including anti-inflammatory and In the last two decades, the chemistry of pyrazolidine-3,5- [3], Phenyl butazone, Kebuzone, Mofebutazone [4] etc. From dione and their fused heterocyclic derivatives have received thepyrazolidine-3,5-diones literatures, it may group be predictede.g., Feprazone that [2], Pyrazolidine-3,5- Sulfinpyrazone considerable attention owing to their synthetic and effective dione moiety represents important pharmacophore and plays biological importance. In spite of a large number of antibiotics a vital role in medicinal agents. A degree of respectability has and chemotherapeutics available for medicinal use, the treatment been bestowed upon Pyrazolidine-3,5-dione derivatives due of infectious diseases still remains an important and challenging to their wide range of biological activities such as antibacterial problem because of a combination of factors including emerging infectious diseases and the increasing number of multi-drug hypoglycemic properties [9]. In the design of new drugs, the resistant microbial pathogens, so it revealed a substantial need combination[5], antifungal of [6],different anti-inflammatory pharmacophores [7], frameanalgesic may [8], lead and to for new classes of antimicrobial agents. There is really perceived need for the discovery of new compounds endowed with different phenyl incorporated Pyrazolidine-3,5-dione displayed varied activity. Through the various molecules designed and synthesized pharmacologicalcompounds with interestingproperties. biologicalPrompted profiles. by these As investigations alkyl, benzyl, for this aim, in recent years, active research has been initiated we synthesized compounds containing Pyrazolidine-3,5-dione Cite this article: Singh R, Upmanyu N, Gupta M, Prasad P (2015) Novel Synthesis, Characterization and Biological Evaluation of Substituted Pyrazolidine-3, 5-Dione. JSM Chem 3(1): 1016. Upmanyu et al. (2015) Email: Central with attached benzoyl group and evaluated them for their anti- R1 OH R1 O CH3OH MATERIALS AND METHODS inflammatory and antimicrobial activity [10]. Conc. H2SO4 O O Chemicals P-Substituted Benzoic Acid Methyl Ester Of Substituted Benzoic Acid All the solvents were of LR grade and were obtained from R1 -R5 Merck, Rankem, Fluka, and S.D. Fine Chemicals. The Melting O C2H5OH R2A/R2B points were recorded in open capillary tubes and are uncorrected. O O O O H using silica gel G. Visualization was done using iodine vapours or N Diethyl Malonate N R2 The purity of the synthesized compounds was confirmed by TLC H R1 sulfuric acid (30% v/v). spectrophotometer. Chemical shifts were expressed in parts Substituted Hydrazide O IR spectra were 13recorded in KBr discs in Nicolet-6700 R2A1 -R2A5 C NMR spectra were recorded on Bruker & R as the solvent, 2 R2B1 -R2B5 6 N N per million (δ) units. HERE, R = NO /OH/Cl/H/NO TMS as an internal standard. Mass spectra were recorded on R1 1 2 2 Avance II 400 MHz apparatus using DMSO-d R2 = H / Ph O O R2A = Ph-NH.NH2 technique and nitrogen analysis was done on elemental analyzer R2B = NH2.NH2.H2O Jeol Sx 102/DA-600 mass spectrometer/Data system using FAB RS-1 - RS-10 Figure 2 Scheme of Synthesis of Title Compound. Elementar Vario EL III Carlo Erba 1108. the Anti-inflammatoryexperimental protocol and wasanalgesic approved activities by the were Animal performed Ethical (Step-1) Synthesis of Different Para Substituted in the animal house of the R.K.D.F College of Pharmacy (M.P.), and Benzoic Acid Methyl Esters (R1 to R5) Committee of R.K.D.F College of Pharmacy (M.P.)-India. (780/05/ ab/CPCSEA).Animals and microbial cultures One mole of substituted benzoic acid was dissolved in 70- chips80 mL were methanol putted and to avoid taken bumping. in a round The bottom whole flask. reaction After mixture it 1.5- 2.0ml sulphuric acid was added from side and some porecelain laboratoryWister albinoconditions rats (120-200 maintained g) and at swiss25±1° Calbino and micefewer (20-30 than cooled to room temperature and equal quantity of water has been g) of either sex were used. The animals housed under standard addedwas subjected to it. This to makesreflux forester 6hrs. and After water refluxing layer separated the mixture but was the two layer was not distinctive one, so for this ester is separated Animal12 / 12 experiments h light /dark were cycle approved and fed by with the standardInstitutional pellet Animal diet with the help of carbon tetrachloride from separating funnel and Ethical(Gold Mohur Committee brand, for Lipton the purpose India Ltd.) of Control and water and Supervisionad libitum. the funnel, removed the sodium bicarbonate layer and tested to seewashed if it waswith basic.0.6M sodiumSeparated bicarbonate. the organic After layer shaking and dried and venting it with the directives of Ministry of Social Justice and Empowerment, of Experiments on Animals (CPCSEA-780), constituted under anhydrous magnesium sulphate & removed the MgSO by gravity Government of India. The microbial cultures of bacteria Proteus 4 mirabilis Pseudomonas aeruginosa ester was obtained which is again recrystallized with ethanol. Bacillus subtilis Staphylococus aureus filtration. Carbon tetrachloride was evaporated and respective were used (MTCC for the 425),evaluation of anti-bacterial activity. (MTCC 424), (MTCC 619) and (MTCC 96) Yield(Step is 89%.- 2) Synthesis of Different substituted Chemistry Hydrazides of Substituted Methyl Benzoates (R2A1 to The preparation of different substituted pyrazolidine-3,5- R2A5 and R2B1 to R2B5) dione by the initial reagent i.e, from substituted benzoic acid consist of three steps [11,12]. Synthesis of the Pyrazolidine-3,5- 0.1mole of different Substituted methyl benzoates previously dissolved in ethanol was taken in round bottom flask and mixed dione derivatives is shown in (figure 2). drops of acetic acid was also added along with some porcelain with 9-10ml of hydrazine hydrate or phenyl hydrazine, 1-2 O R2 chips. The whole system is subjected to reflux for 8-9 hrs. After N N refluxing product (respective hydrazide) was obtained which is O again(Step-3) recrystallize Synthesis with of absolute Different ethanol? Substituted Yield is 73%. 1-benzoyl- pyrazolidine-3,5-dione (RS-1 to RS-10) R 1 O After the successful completion of the above two steps the Figure 1 Basic Molecule. last step concludes the reaction with cyclisation, the formation JSM Chem 3(1): 1016 (2015) 2/7 Upmanyu et al. (2015) Email: Central of different substituted pyrazolidine-3,5-dione molecule group received an equivalent amount of CMC. To one group the was carried out. For this equimolar quantity of the different substituted hydrazide was reacted with diethyl malonate to wasstandard injected drug into Indomethacin the sub plantar (10 mg/kg) tissue ofwas the administered. left paw of all After the one hour, carrageen an (0.1 mL, 1% w/v solution in sterile saline) obtainBiological the final Evaluation product. Yield is 41%. In biological evaluation antibacterial activity and anti- animals. The right paw served as the reference non-inflamed paw for comparison [18]. The initial paw volume was measured using percentagea plethysmograph of reduction within in30 theseconds paw ofvolume the injection. was calculated After three by inflammatoryAnti-Bacterial activity Activity was performed. subtractinghours, the final the pawdifference volume between of each theanimal right was and measured. left hind pawThe The newly synthesized compounds were screened for volumes in the treated group from the difference in the control their antibacterial activity against bacterial strains by disc group and dividing it by the difference in the control group.
Recommended publications
  • Prezentace Aplikace Powerpoint
    Analgesics - antipyretics = „weak“ analgesics = non-opioid analgesics Most of them also • non-steroidal anti-inflamatory drugs (NSAIDs) •antirheumatics Oldřich Farsa 2011 Metabolism of eicosanoids O O arachidonic O H acid = 2 C O R1 R2 OH R2 O OH CH C O P O + 3 H N CH 2 O 3 CH3 glucocorticoids inhibitors of phspholipase A2 prostaglandins sythesis = COOH = "weak" analgesics + lipoxygenase inhibitors + NSAIDs arachidonic acid cyclooxygenases (COX1 + COX2) lipoxygenase OOH O COOH COOH O PG 5-hydroperoxy-6-trans-8,11,14-cis-eikosatetraenoic acid G2 OOH (5-HPETE) cyklooxygenases tromboxan synthase prostacyklin synthase PG H2 PG I2 = prostacyklin TX A2 endothelium cells LT A4 trombocytes isomerases PG D2 PG E2 LT C4 LT B4 PG F2α all the cells LT D4 LT E4 Effects of prostaglandins ↓ Prostaglandin E, F2α : ache, fewer, inflammation, sekretion of HCl , stomach mucosa capilaries dilatation, contraction of + ↑ uterus, kidneys: excretion of Na and H2O Prostacyclin (prostaglandin I ): vasodilatation, platelets aggregation inhibition 2 Tromboxan: vasokonstriction, platelets aggregation activation Leukotriens: alergic reactions (e.g. asthma bronchiale) Cyklooxygenases (= prostaglandin G/H synthases) COX1 Constitutive: in all the tissues Functions: •protection of stomach mucosa (vasodilatation) •diuresis •platelets aggregation (TXA) COX2 Philipp Needlemann Constitutive: kidneys, brain (co-localized with cyclins D and E) inventor of COX 1 isoenzymes Inducible: macrophages, neutrophfils, fibroblasts, endothelium cells (1989) Functions: •vasodilatation
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0156582 A1 Tsukamoto Et Al
    US 20090156582A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0156582 A1 Tsukamoto et al. (43) Pub. Date: Jun. 18, 2009 (54) PYRAZOLE COMPOUND Publication Classification (76) Inventors: Tetsuya Tsukamoto, Osaka-shi, (51) Int. Cl. Osaka (JP); Takeshi Yamamoto, A6II 3/55 (2006.01) Osaka-shi,Osaka (JP); Ryosuke A63L/454 (2006.01) Tokunoh, Osaka-shi, Osaka (JP); A63L/462 (2006.01) Tomohiro Kawamoto, Osaka-shi, C07D 403/02 (2006.01) Osaka (JP); Masahiro Okura, Osaka-shi, Osaka (JP); Masakumi (52) U.S. Cl. .................... 514/217.09: 514/406; 514/326; Kori, Osaka-shi, Osaka (JP); 548/364.1: 548/368.4: 546/211; 540/603 Katsuhito Murase, Osaka-shi, Osaka (JP) (57) ABSTRACT Correspondence Address: The present invention provides a pyrazole compound repre WENDEROTH, LIND & PONACK, L.L.P. sented by the formula (I): 1030 15th Street, N.W., Suite 400 East Washington, DC 20005-1503 (US) b (Io) (21) Appl. No.: 11/884,054 Ra R (22) PCT Filed: Feb. 9, 2006 (86). PCT No.: PCT/UP2006/302686 S371 (c)(1), wherein ring Ao is a pyrazole ring optionally further having 1 (2), (4) Date: Sep. 14, 2007 or 2 substituents; R is a substituted carbamoyl group; and R' (30) Foreign Application Priority Data is an optionally Substituted acylamino group, or a salt thereof or a prodrug thereof, which is useful as an agent for the Feb. 9, 2005 (JP) .................................. O333562005 prophylaxis or treatment of GSK-3? related pathology or Dec. 22, 2005 (JP) .................................. 3709622005 disease, and a GSK-3? inhibitor including same. US 2009/0156582 A1 Jun.
    [Show full text]
  • Sleason, Redwood City, CA (US), Juan W. W333. a 3. C
    USOO8288373B2 (12) United States Patent (10) Patent No.: US 8,288,373 B2 Chen et al. (45) Date of Patent: Oct. 16, 2012 (54) MODULATORS OF CXCR7 FOREIGN PATENT DOCUMENTS AU 2006-230674 A1 11, 2006 (75) Inventors: Xi Chen, Palo Alto, CA (US); Pingchen WO WOO2,08221 A2 1, 2002 Fan, Fremont, CA (US); Mark M. WO WOO3,O764OO A1 9, 2003 Sleason, Redwood City, CA (US), Juan W. W333. A 3. C. Jaen, Burlingame, CA (US). Lianfa WO WO 2007/126935 A2 11/2007 Li, Palo Alto, CA (US); Jeffrey P. WO WO 2008/008518 A1 1/2008 McMahon, Mountain View, CA (US); WO 2008, 11215.6 A1 9, 2008 Jay Powers, Pacifica, CA (US); Yibin Zeng, Foster City, CA (US); Penglie OTHER PUBLICATIONS Zhang, Foster City, CA (US) Konishi et al. (Yakugaku Zasshi (1973), 93(5), 684-7). Abstract.* r Miao et al., “CXCR7 (RDC1) promotes breast and lung tumor growth (73) Assignee: Chemocentryx, Inc., Mountain View, in vivo and is expressed on tumor-associated vasculature.” 2007. CA (US) PNAS, vol. 104. No. 40, pp. 15735-15740. c Zabel et al., “Elucidation of CXCR-7-Mediated Signaling Events and (*) Notice: Subject to any disclaimer the term of this Inhibition of CXCR4-Mediated Tumor Cell Transendothelial Migra patent is extended or adjusted under 35 tion by CXCR7 Ligands.” The Journal of Immunology, 2009, vol. U.S.C. 154(b) by 171 days. 183, Issue 5, pp. 3204-3211. International Search Reportmailed on Jan. 27, 2010, for International (21) Appl. No.: 12/612,638 Application No. PCT/US09/63298 filed on Nov.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]
  • Antagonists of Il-6 to Prevent Or Treat
    (19) TZZ ¥_ _T (11) EP 2 376 126 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 39/00 (2006.01) C07K 16/24 (2006.01) 20.12.2017 Bulletin 2017/51 (86) International application number: (21) Application number: 09830695.4 PCT/US2009/006266 (22) Date of filing: 24.11.2009 (87) International publication number: WO 2010/065077 (10.06.2010 Gazette 2010/23) (54) ANTAGONISTS OF IL-6 TO PREVENT OR TREAT THROMBOSIS ANTAGONISTEN VON IL-6 ZUR PRÄVENTION ODER BEHANDLUNG VON THROMBOSE ANTAGONISTES D IL-6 POUR PRÉVENIR OU TRAITER LA THROMBOSE (84) Designated Contracting States: • MATSUYAMA MASASHI ET AL: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR "Anti-interleukin-6 receptor antibody HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL (tocilizumab) treatment of multicentric PT RO SE SI SK SM TR Castleman’s disease", INTERNAL MEDICINE, JAPANESE SOCIETY OF INTERNAL MEDICINE, (30) Priority: 05.02.2009 US 366567 TOKYO, JP; BIOSCIENCES INFORMATION 14.07.2009 US 502581 SERVICE, PHILADELPHIA, PA, US, vol. 46, 1 25.11.2008 US 117811 P January 2007 (2007-01-01), pages 771-774, 25.11.2008 US 117861 P XP002696891, ISSN: 0918-2918, DOI: 24.02.2009 US 391717 10.2169/INTERNALMEDICINE.46.6262 06.03.2009 US 399156 • EMILLE D ET AL: "ADMINISTRATION OF AN 25.11.2008 US 117839 P ANTI-INTERLEUKIN-6 MONOCLONAL 24.02.2009 US 391615 ANTIBODY TO PATIENTS WITH ACQUIRED IMUNODEFICIENCY SYNDROME AND (43) Date of publication of application: LYMPHOMA: EFFECT ON LYMPHOMA GROWTH 19.10.2011 Bulletin 2011/42 AND ON B CLINICAL SYMPTOMS", BLOOD, AMERICAN SOCIETY OFHEMATOLOGY, US, vol.
    [Show full text]
  • Objective Salicylate Propionic Acid Derivatives Acetic Acid
    Semester-IV Sub Name-medicinal chemistry-I (sub code-BP-402T) Objective Sodium salicylate, Aspirin, Mefenamic acid*, Meclofenamate, Indomethacin, Sulindac, Tolmetin, Zomepriac, Diclofenac, Ketorolac, Ibuprofen*, Naproxen, Piroxicam, Phenacetin, Acetaminophen, Antipyrine, Phenylbutazone. 1. INTRODUCTION A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti- inflammatory agents block certain substances in the body that cause inflammation. They are used to treat many different conditions. Some anti-inflammatory agents are being studied in the prevention and treatment of cancer. 1.1 CLASSIFICATION NSAIDs can be classified based on their chemical structure or mechanism of action. Older NSAIDs were known long before their mechanism of action was elucidated and were for this reason classified by chemical structure or origin. Newer substances are more often classified by mechanism of action. Salicylate • Aspirin (acetylsalicylic acid) • Diflunisal (Dolobid) • Salicylic acid and its salts Propionic acid derivatives • Ibuprofen • Dexibuprofen • Naproxen • Fenoprofen • Ketoprofen • Dexketoprofen Acetic acid derivatives • Indomethacin • Tolmetin • Sulindac • Ketorolac • Diclofenac • Aceclofenac • Nabumetone (drug itself is non-acidic but the active, principal metabolite has a carboxylic acid group) Enolic acid (oxicam) derivatives • Piroxicam • Meloxicam • Tenoxicam • Droxicam • Lornoxicam • Isoxicam (withdrawn from market 1985) • Phenylbutazone Anthranilic acid derivatives (fenamates) The following NSAIDs are
    [Show full text]
  • Søgeprotokol for Nationale Kliniske Retningslinjer
    Søgeprotokol for nationale kliniske retningslinjer Projekttitel/aspekt NKR behandling af patienter med lumbal spinalstenose – Søgning efter primærlitteratur Fagkonsulent /projektleder Rikke Rousing / Maria Herlev Ahrenfeldt Søgespecialist Kirsten Birkefoss Senest opdateret 23.12.2016 Fokuserede spørgsmål Bør patienter med lumbal spinalstenose have tilbudt aktiv PICO 1: behandling i form af superviseret træning fremfor vanlig behandling? PICO 2: Bør patienter med lumbal spinalstenose have tilbudt ledmobiliserende behandling frem for vanlig behandling? PICO 3: Bør patienter med lumbal spinalstenose have tilbudt paracetamol frem for ingen smertestillende behandling? PICO 4: Bør patienter med lumbal spinalstenose have tilbudt non steroid antiinflammatorisk medicin (NSAID) frem for ingen smertestillende behandling? PICO 5: Bør patienter med lumbal spinalstenose have tilbudt smertestillende medicin i form af opioider i tillæg til eventuel behandling med svage smertestillende? PICO 6: Bør patienter med lumbal spinalstenose have tilbudt muskelrelaxantia i tillæg til eventuel behandling med svage smertestillende? PICO 7: Bør patienter med lumbaspinalstenose have tilbudt medicin for neuropatiske smerter? PICO 8: Bør patienter med lumbal spinalstenose have tilbudt kirurgisk dekompression i tilfælde af manglende effekt af ikke kirurgisk behandling? PICO 9: Bør patienter med lumbal spinalstenose have tilbudt stivgørende operation med eller uden instrumentering i tillæg til dekompression? PICO 10: Bør patienter opereret for lumbal spinalstenose tilbydes
    [Show full text]
  • Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine 2013
    Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine, Pyrimidine, Azaindole, Quinoline, Thiazole, Isatin, Phenanthrene, Thiophene We declare that some of the listed products might be protected by valid patents. They are only for scientific research and development purpose. They are not offered for sales in countries where the sales of such products constitutes patents infringement. The liability for patents checking and patents infringement is exclusive at buyers risk! I2CNS LLC CANNOT BE HELD LIABLE FOR ANY VIOLATIONS OF PATENT RIGHTS CAUSED BY CUSTOMERS. CAS No. Product Name and Description 26988-72-7 1-METHYL-DL-TRYPTOPHAN 68886-07-7 2-Fluoro-4-hydroxyphenylaceticacid 72607-53-5 N-(3-AMINOPROPYL)METHACRYLAMIDE 171049-41-5 7-AMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLICACIDTERT- BUTYLESTER 885280-38-6 (3-OXO-CYCLOHEXYL)-CARBAMICACIDTERT-BUTYLESTER 186826-86-8 MOXIFLOXACIN HCL 102735-53-5 L-CYCLOPROPYLALANINE 145100-50-1 2-[N,N-BIS(TRIFLUOROMETHYLSULFONYL)AMINO]PYRIDINE 143491-57-0 Emtricitabine 39809-25-1 2-Amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3,9-dihydropurin-6-one 147127-20-6 Tenofovir 716-39-2 2,3-NAPHTHALENEDICARBOXYLICANHYDRIDE 4333-62-4 1,3-DIMETHYLIMIDAZOLIUMIODIDE 108-45-2 m-Phenylenediamine 1961-72-4 R-(3)-HYDROXYMYRISTICACID 131-48-6 N-Acetylneuraminicacid 88196-70-7 (R)-1-(3-Methoxyphenyl)ethylamine 680-31-9 Hexamethylphosphoramide 486-66-8 Daidzein 872-50-4 1-Methyl-2-pyrrolidinone 425378-68-3 2-FLUORO-5-NITROPHENYLBORONICACIDPINACOLESTER 115651-29-1 5-ACETYL-2-AMINO-4-HYDROXYBENZOICACID 115269-99-3 N,N-BIS-BOC-N-ALLYLAMINE
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Documents Numérisés Par Onetouch
    19 ORGANISATION AFRICAINE DE LA PROPRIETE INTELLECTUELLE 51 8 Inter. CI. C07D 471/04 (2018.01) 11 A61K 31/519 (2018.01) N° 18435 A61P 29/00 (2018.01) A61P 31/12 (2018.01) A61P 35/00 (2018.01) FASCICULE DE BREVET D'INVENTION A61P 37/00 (2018.01) 21 Numéro de dépôt : 1201700355 73 Titulaire(s): PCT/US2016/020499 GILEAD SCIENCES, INC., 333 Lakeside Drive, 22 Date de dépôt : 02/03/2016 FOSTER CITY, CA 94404 (US) 30 Priorité(s): Inventeur(s): 72 US n° 62/128,397 du 04/03/2015 CHIN Gregory (US) US n° 62/250,403 du 03/11/2015 METOBO Samuel E. (US) ZABLOCKI Jeff (US) MACKMAN Richard L. (US) MISH Michael R. (US) AKTOUDIANAKIS Evangelos (US) PYUN Hyung-jung (US) 24 Délivré le : 27/09/2018 74 Mandataire: GAD CONSULTANTS SCP, B.P. 13448, YAOUNDE (CM). 45 Publié le : 15.11.2018 54 Titre: Toll like receptor modulator compounds. 57 Abrégé : The present disclosure relates generally to toll like receptor modulator compounds, such as diamino pyrido [3,2 D] pyrimidine compounds and pharmaceutical compositions which, among other things, modulate toll-like receptors (e.g. TLR-8), and methods of making and using them. O.A.P.I. – B.P. 887, YAOUNDE (Cameroun) – Tel. (237) 222 20 57 00 – Site web: http:/www.oapi.int – Email: [email protected] 18435 TOLL LIKE RECEPTOR MODULATOR COMPOUNDS CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority to U.S. Provisional Application Nos. 62/128397, filed March 4, 2015, and 62/250403, filed November 3, 2015, both of which are incorporated herein in their entireties for all purposes.
    [Show full text]
  • 2 12/ 35 74Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 22 March 2012 (22.03.2012) 2 12/ 35 74 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/16 (2006.01) A61K 9/51 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 9/14 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/EP201 1/065959 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 14 September 201 1 (14.09.201 1) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, (25) Filing Language: English RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, (26) Publication Language: English TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/382,653 14 September 2010 (14.09.2010) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant (for all designated States except US): GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, NANOLOGICA AB [SE/SE]; P.O Box 8182, S-104 20 ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, Stockholm (SE).
    [Show full text]
  • Non-Steroidal Anti-Inflammatory Drugs in Parkinson's Disease
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by OAR@UM Experimental Neurology 205 (2007) 295–312 www.elsevier.com/locate/yexnr Review Non-steroidal anti-inflammatory drugs in Parkinson's disease Ennio Esposito a, Vincenzo Di Matteo a, Arcangelo Benigno b, Massimo Pierucci a, ⁎ Giuseppe Crescimanno b, Giuseppe Di Giovanni b, a Istituto di Ricerche Farmacologiche “Mario Negri”, Consorzio “Mario Negri” Sud, Santa Maria Imbaro (Chieti), Italy b Dipartimento di Medicina Sperimentale, Sezione di Fisiologia Umana, “G. Pagano”, Università degli Studi di Palermo, Corso Tuköry 129, 90134 Palermo, Italy Received 21 November 2006; revised 5 February 2007; accepted 13 February 2007 Available online 23 February 2007 Abstract Parkinson's disease (PD) is known to be a chronic and progressive neurodegenerative disease caused by a selective degeneration of dopaminergic (DAergic) neurons in the substantia nigra pars compacta (SNc). A large body of experimental evidence indicates that the factors involved in the pathogenesis of this disease are several, occurring inside and outside the DAergic neuron. Recently, the role of the neuron–glia interaction and the inflammatory process, in particular, has been the object of intense study by the research community. It seems to represent a new therapeutic approach opportunity for this neurological disorder. Indeed, it has been demonstrated that the cyclooxygenase type 2 (COX-2) is up- regulated in SNc DAergic neurons in both PD patients and animal models of PD and, furthermore, non-steroidal anti-inflammatory drugs (NSAIDs) pre-treatment protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) or 6 hydroxydopamine (6-OHDA)-induced nigro- striatal dopamine degeneration.
    [Show full text]